IM 18
Alternative Names: IM-18Latest Information Update: 08 Dec 2023
At a glance
- Originator Beijing Immunochina Medical Science and Technology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malignant melanoma
Most Recent Events
- 11 Oct 2023 Preclinical trials in Malignant melanoma in China (Parenteral) prior to October 2023 (Beijing Immunochina Medical Science and Technology pipeline, October 2023)